Main content area

Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins

Bloomquist, Cameron J., Mecham, Michael B., Paradzinsky, Mark D., Janusziewicz, Rima, Warner, Samuel B., Luft, J. Christopher, Mecham, Sue J., Wang, Andrew Z., DeSimone, Joseph M.
Journal of controlled release 2018 v.278 pp. 9-23
biocompatibility, drugs, encapsulation, geometry, image analysis, ingredients, liquids, manufacturing, medical equipment, medicine, models, polyethylene glycol, resins
Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine.